BioTech (Shanghai) Chairman Jim Wu attended the 2025 Heartland Connect for Trade & Investment Conference, hosted by USHCA, engaging leaders from Mayo Clinic’s DMC and U.S. healthcare organizations. The event fostered dialogue on AI, healthcare access, and innovation, advancing U.S.–China collaboration and helping Chinese MedTech firms enter the American market.

SaniMed Science Group (USA) has partnered with Gary Carruthers, former Medtronic executive and GI technology expert, as Market Advisor to guide Asian—especially Chinese—MedTech firms in R&D, FDA approval, and market entry. Together with BioTech (Shanghai), SaniMed is building a dual-platform to help Chinese innovators truly enter the U.S. healthcare market.

On June 3, 2025, SaniMed Founder Jim Wu attended the “Build a Biotech” Forum hosted by JLABS in Houston. The event focused on turning biotech innovations into sustainable businesses. With leaders from JJDC and the global biotech ecosystem, the forum explored strategies for funding, IP, and commercialization. SaniMed continues to foster global collaboration in life sciences innovation.

Jim Wu, founder of SaniMed and Chairman of BioTech, participated in the University of Houston Bauer College of Business SURE Program Impact Forum. He discussed empowering startups and promoting sustainable community development with Dr. Rana Dajani and local leaders, highlighting the role of innovation in strengthening Houston’s economy and fostering social responsibility.

Torskal SAS, a French oncology innovator developing non-ionizing plasmonic PTT for cancers, has partnered with Houston-based SaniMed as its fundraising and strategic business consultant for US and international markets. SaniMed’s expertise in life science investments and commercialization will drive Torskal’s expansion and clinical development. The alliance accelerates breakthrough treatment advancements.